Quick Answer
ADC Therapeutics SA reported Shares Outstanding of 125.75 million shares for fiscal year 2025.
ADC Therapeutics SA Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 125.75M | +27.2% |
| 2024 | 98.86M | +20.1% |
| 2023 | 82.29M | +2.0% |
| 2022 | 80.64M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 112.63M | +16.5% | +0.1% |
| June 30, 2025 | 112.50M | +16.6% | +13.4% |
| March 31, 2025 | 99.18M | +19.8% | +0.3% |
| December 31, 2024 | 98.86M | +20.1% | +2.2% |
| September 30, 2024 | 96.69M | — | +0.2% |
| June 30, 2024 | 96.47M | — | +16.5% |
| March 31, 2024 | 82.78M | — | +0.6% |
| December 31, 2023 | 82.29M | — | — |
- ADC Therapeutics SA showed an increase of +27.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2022–2025 period, ADC Therapeutics SA’s shares outstanding has grown by 55.9% (from 80.64 million shares to 125.75 million shares).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: